Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Placebo powder

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,630 result(s) found for: Placebo powder. Displaying page 1 of 82.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2007-005107-17 Sponsor Protocol Number: 1184.15 Start Date*: 2008-01-28
    Sponsor Name:Boehringer Ingelheim bv
    Full Title: A 24-week (+ 24 week extension), randomized, placebo-controlled (only 1st 12-week period), double–blind, parallel-group, efficacy and safety comparison of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhal...
    Medical condition: Moderate to severe COPD
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    9.1 10010953 COPD exacerbation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) ES (Completed) FI (Completed) DE (Prematurely Ended) PT (Prematurely Ended) BE (Completed) FR (Completed) SE (Prematurely Ended) DK (Prematurely Ended) LV (Prematurely Ended) HU (Prematurely Ended) LT (Prematurely Ended) EE (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended) AT (Prematurely Ended) SK (Completed)
    Trial results: View results
    EudraCT Number: 2007-005134-36 Sponsor Protocol Number: 1184.14 Start Date*: 2008-01-28
    Sponsor Name:Boehringer Ingelheim bv
    Full Title: A 24-week (+ 24 week extension), randomized, placebo-controlled (only 1st 12-week period), double–blind, parallel-group, efficacy and safety comparison of Tiotropium/Salmeterol (7.5 µg/25 µg) Inhal...
    Medical condition: Moderate to severe COPD
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    9.1 10010953 COPD exacerbation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) ES (Completed) FI (Completed) PT (Prematurely Ended) DE (Prematurely Ended) BE (Completed) DK (Completed) FR (Completed) SE (Prematurely Ended) IT (Prematurely Ended) LV (Prematurely Ended) GR (Completed) LT (Prematurely Ended) EE (Prematurely Ended) SK (Completed) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-004229-10 Sponsor Protocol Number: DESCIFRA03 Start Date*: 2014-07-07
    Sponsor Name:Raul de la Fuente-Fernandez
    Full Title: Placebo responses in different stages of frontostriatal dysfunction in Parkinson's disease
    Medical condition: Parkinson's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-003294-66 Sponsor Protocol Number: INS1009-211 Start Date*: 2022-06-01
    Sponsor Name:Insmed Incorporated
    Full Title: A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Hyperten...
    Medical condition: Pulmonary Hypertension Associated with Interstitial Lung Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10077731 Pulmonary hypertension WHO functional class I LLT
    20.0 100000004855 10077732 Pulmonary hypertension WHO functional class II LLT
    20.0 100000004855 10077733 Pulmonary hypertension WHO functional class III LLT
    20.0 100000004855 10077734 Pulmonary hypertension WHO functional class IV LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-021638-72 Sponsor Protocol Number: HZC113782 Start Date*: 2011-06-09
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: HZC113782: A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmo...
    Medical condition: Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10038738 - Respiratory, thoracic and mediastinal disorders 10009033 Chronic obstructive pulmonary disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) LV (Completed) AT (Completed) DE (Completed) GB (Completed) DK (Prematurely Ended) PL (Completed) GR (Completed) BG (Completed) ES (Completed) IT (Completed) NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000586-20 Sponsor Protocol Number: GS-US-174-0144 Start Date*: 2013-01-23
    Sponsor Name:Gilead Sciences Inc.
    Full Title: A Randomized, Double-Blind Evaluation of the Antiviral Efficacy, Safety, and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Patients with Chronic Hepatitis B Infection
    Medical condition: Chronic Hepatitis B
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: PL (Prematurely Ended) BG (Prematurely Ended) Outside EU/EEA RO (Trial now transitioned)
    Trial results: View results
    EudraCT Number: 2021-001528-16 Sponsor Protocol Number: INS1009-202 Start Date*: 2022-05-30
    Sponsor Name:Insmed Incorporated
    Full Title: A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to valuate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in participants with Pu...
    Medical condition: Participants with Pulmonary Arterial Hypertension
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10064911 Pulmonary arterial hypertension PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Trial now transitioned) AT (Trial now transitioned) DK (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-004169-41 Sponsor Protocol Number: CQAB149B2329 Start Date*: 2006-01-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 52-week treatment, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety and tolerability of indacaterol (200 & 400 µg o.d) in patients wi...
    Medical condition: Chronic obstructive pulmonary disease (COPD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005469-12 Sponsor Protocol Number: NEO-012 Start Date*: 2006-01-06
    Sponsor Name:Neolab Limited
    Full Title: A Phase III, randomised, double-blind, double-dummy cross-over study to compare two dry powder inhaled formulations of budesonide on methacholine hyper-reactivity in patients with stable, persisten...
    Medical condition: Stable, persistent, moderate asthma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002318-22 Sponsor Protocol Number: CTBM100C2303 Start Date*: 2009-09-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study in Cystic Fibrosis (CF) Subjects to Assess Efficacy, Safety and Pharmacokinetics of Tobramycin Inhalation Powder from a ...
    Medical condition: Pseudomonas aeruginosa infection in cystic fibrosis patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021860 Infection pseudomonas aeruginosa LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: LT (Completed) LV (Completed) EE (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2010-019466-81 Sponsor Protocol Number: LPA114255 Start Date*: 2016-12-12
    Sponsor Name:GlaxoSmithKline Research & Development
    Full Title: A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Five-Treatment, Four 6-Week Period Cross-Over, Multi-Center Study to Evaluate the Effect of Adding GSK2190915 100 mg, GSK2190915 300 mg...
    Medical condition: Asthma
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2006-000391-32 Sponsor Protocol Number: 20102D05 Start Date*: 2006-06-06
    Sponsor Name:Britannia Pharmaceuticals Limited
    Full Title: A 2 Treatment Period Study with Period 1 Comprising a 3-Week Randomised, Double-Blind, Crossover Comparison of Apomorphine Nasal Powder (2 and 4 mg) and Placebo in Combination with a 12-Week Open, ...
    Medical condition: Alleviation of acute episodes of motor symptoms associated with Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061536 Parkinson's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Prematurely Ended) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004216-31 Sponsor Protocol Number: CIGE025E2201 Start Date*: 2012-03-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase II, multi-centre, randomized, double blind, placebo-controlled study to determine the mode of action of omalizumab in patients with chronic idiopathic urticaria (CIU) who remain symptomatic...
    Medical condition: Chronic Idiopathic Urticaria
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10009159 Chronic urticaria LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001542-29 Sponsor Protocol Number: 106260 Start Date*: 2015-06-22
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A phase IIIb, randomized, double-blind, placebo-controlled study to explore the existence of horizontal transmission of the RIX4414 vaccine strain between twins within a family.
    Medical condition: Rotavirus (RV) gastroenteritis
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-023959-28 Sponsor Protocol Number: GS-US-219-0104 Start Date*: 2011-07-04
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for Inhalation Solution/Aztreonam 75 mg Powder and Solvent for Nebuliser Solutio...
    Medical condition: Non-CF bronchiectasis and gram-negative endobronchial infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10006445 Bronchiectasis PT
    14.1 10021881 - Infections and infestations 10070295 Infective exacerbation of bronchiectasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) NL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-023227-26 Sponsor Protocol Number: Repha_1352 Start Date*: 2010-12-17
    Sponsor Name:Repha GmbH
    Full Title: Randomized, prospective double-blinded study to evaluate safety and efficacy of Angocin Anti-Infekt N versus placebo in the prophylaxis of respiratory tract infections
    Medical condition: Prophylaxis of respiratory tract infections
    Disease: Version SOC Term Classification Code Term Level
    12.1 10066740 Acute respiratory tract infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-019989-91 Sponsor Protocol Number: LPA114387 Start Date*: 2010-11-25
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Three-Treatment, Three 6-Week Period Cross-Over, Multi-Center Exploratory Study to Evaluate the Effect of Adding GSK2190915 300mg Table...
    Medical condition: Asthma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2020-003147-29 Sponsor Protocol Number: ACT-01_P2_01 Start Date*: 2020-11-06
    Sponsor Name:ACCURE TX FRANCE SASU
    Full Title: A two-arm randomized double-blind placebo-controlled monocentric study to evaluate the safety and tolerability of ACT-01 compared to placebo in patients with acute optic neuritis
    Medical condition: Subjects from 18 to 60 years old with a diagnosis of a unilateral Acute Optic Neuritis with a demyelinating origin, whose symptoms have appeared in the last 10 days before randomization and whose e...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001395-37 Sponsor Protocol Number: Repha_1430 Start Date*: 2018-07-30
    Sponsor Name:Repha GmbH
    Full Title: Investigation of the efficacy and safety of ANGOCIN® Anti-Infekt N versus placebo in adult patients with acute bronchitis. A multicenter, randomized, double-blind, placebo-controlled, parallel-grou...
    Medical condition: acute bronchitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10006452 Bronchitis acute LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-003024-46 Sponsor Protocol Number: Repha_1412 Start Date*: 2014-09-19
    Sponsor Name:Repha GmbH
    Full Title: Efficacy, safety and tolerability of Angocin Anti-Infekt N versus Placebo for MRSA eradication
    Medical condition: MRSA colonisation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10004017 Bacterial disease carrier PT
    20.0 10021881 - Infections and infestations 10068296 MRSA colonisation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jul 07 09:42:11 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA